2021年11月17日至18日|虚拟的
亚洲疫苗世界大会
新加坡
800+
参会嘉宾
200+
参会企业和机构
50+
演讲嘉宾
20+
会下交流时间
峰会 概念
由于医疗保健支出的增加，疫苗技术的发展以及对预防性疫苗（尤其是新的COVID-19疫苗）的需求不断增长，亚太预防性疫苗市场每年将以12.89%的速度增长，到2020年之间的可寻址市场总额将达到$97.2亿和2026年。
最近，冠状病毒感染已经感染了全球数百万人。在某些地区，社区传播导致全球人员伤亡增加。目前，Big pharma和biopharma正在将精力集中在COVID-19疫苗的研发上。 COVID-19大流行形势产生了空前的需求，公司在政府的支持和技术进步的支持下大力投入研发活动，以缩短临床试验时间并提高生产效率。为了满足不断增长的需求，扩大疫苗生产设施将增强市场的增长前景。
2021年亚洲疫苗世界大会将是亚洲唯一以疫苗为中心的平台，它将全球合作伙伴和地区利益相关者聚集在一起，以利用合作机会，了解最新的技术进步和带头的科学创新。该活动将主办大型制药公司，国际生物制药公司，亚洲生物制药公司，学术与研究机构，监管机构，非政府组织，解决方案提供商和技术专家。
在本届《亚洲疫苗世界》上，我们与亚太地区疫苗卓越奖并列。如果亚洲的疫苗业务对您来说很重要，那么2021年亚洲疫苗世界大会将是您的理想之选！
会议 议程
亚洲疫苗世界大会将是新加坡唯一的针对亚洲的疫苗平台，它将汇集全球合作伙伴和地区利益相关者，以利用合作机会，了解最新的技术进步和带头的科学创新。该活动将主办BIG Pharma，国际生物制药公司，亚洲生物制药公司，学术与研究机构，监管机构，非政府组织，解决方案提供商和技术专家。如果亚洲的疫苗业务对您来说很重要，那么《亚洲疫苗世界2021》就是您的理想之选！
现在注册！
2021 演讲嘉宾
Jerome H. Kim 国际疫苗研究所
M.D, Director General国际疫苗研究所南韩 Jerome Kim, M.D., is an international expert on the evaluation and development of vaccines and is the Director-General of the International Vaccine Institute (IVI), whose mission is to discover, develop and deliver safe, effective, and affordable vaccines for Global Health. His depth and breadth of scientific experience span basic research through advanced clinical development. IVI’s oral cholera vaccine is used around the world to prevent this deadly diarrheal disease. IVI is working on several different vaccines against COVID-19, including the clinical testing of Inovio’s DNA vaccine at Seoul National University Hospital and Genexine’s COVID-19 vaccine at Severance Hospital.
Dr. Kim was Principal Deputy and Chief, Laboratory of Molecular Virology and Pathogenesis in the U.S. Military HIV Research Program (MHRP) and also served as the Project Manager for the HIV Vaccines and Advanced Concepts Evaluation Project Management Offices, U.S. Army Medical Materiel Development Activity, Fort Detrick, MD. He led the Army's Phase III HIV vaccine trial (RV144) which was the first demonstration that an HIV vaccine could protect against infection, as well as subsequent studies that identified laboratory correlates and HIV sequence changes associated with vaccination.
Dr. Kim has authored over 300 publications and received the John Maher Award for Research Excellence from the Uniformed Services University of the Health Sciences in 2013 and the Department of the Army R&D Award for Technical Excellence (2013). Dr. Kim is also an Adjunct Professor of Medicine at the Uniformed Services University of the Health Sciences and at Yonsei University Graduate School of Public Health and a Fellow of the American College of Physicians and the Infectious Diseases Society of America.
He is a graduate of the University of Hawaii, with high honors in History and highest honors in Biology, and received his M.D. from Yale University School of Medicine.
Zhong Kai Shi Yisheng Biopharma
Ph.D, Chief Medical OfficerYisheng Biopharma中国Dr. Shi brings over 20 years of experience in global product development. Prior to joining Yisheng, Dr. Shi led global product development as Director of Clinical Development at the vaccine development organization Aeras. Before Aeras, Dr. Shi was Director of Vaccine Development at Altimmune. He received his M.D. from Beijing University and earned an MBA from the University of Alabama at Birmingham.
Han S Kierstead AIVITA Biomedical
首席执行官AIVITA Biomedical美国 Dr. Keirstead is an internationally known stem cell expert and serial entrepreneur that has led therapy development for cancer, immune disorders, motor neuron diseases, spinal cord injury, and retinal diseases. He is the Chairman and CEO of AIVITA Biomedical. He has founded 4 successful biotechnology companies, each returning significant value to investors and treatments to patients. He holds Board positions in several prominent biotechnology companies. He was a full Professor at the University of California, Irvine where he founded, directed, and erected a building for the UCI Stem Cell Research Center. He was a founding advisor of the California Stem Cell Initiative that resulted in a $3 billion stem cell fund (CIRM). He has been a long-time advisor to several governments on biomedical policy. Dr. Keirstead received his Ph.D. in neuroscience from the University of British Columbia, Canada, receiving the Cameron Award for outstanding Ph.D. thesis in the country. He received the distinct honor of election as Senate Member of the University of Cambridge and Fellow of the Governing Body of Downing College and was the youngest member to have been elected to those positions.
牧场埃拉 巴拉特生物技术公司
项目负责人：SARS-CoV-2疫苗巴拉特生物技术公司印度
Mark Newman GeoVax
Chief Scientific Officer, GeoVax, USA GeoVax美国 Dr. Newman has more than 30 years of experience in the biotechnology sector serving in senior management roles at GeoVax (Atlanta, GA), PaxVax (San Diego, CA), Pharmexa (Horsholm, Denmark), Epimmune (San Diego, CA), Vaxcel (Atlanta, GA), Apollon (Philadelphia, PA) and Cambridge Biotech (Boston, MA) where he directed research, development and early-stage clinical testing of protein, peptide, plasmid DNA and viral vectored vaccines and multiple vaccine adjuvants. He participated with or directed teams responsible for the transition of 10 vaccine or vaccine-related products from the research stage to Phase 1 and 2 clinical testings. He also served as the primary scientific director for multiple corporate teams that completed Due Diligence reviews, technology assessments, and intellectual property reviews, and portfolio management to support strategic planning, technology in-licensing, and out-licensing, corporate partnering, and mergers and acquisitions.
Dr. Newman has co-authored more than 100 scientific papers, reviews, and book chapters during his professional career. He is a named co-inventor on multiple issued US and PCT patents, all related to vaccine technologies. He served as the Principal Investigator on multiple USA government and foundation grants and contracts and has served as a grant and contract review expert for 20 years for the National Institutes of Health.
Dr. Newman is a graduate of the Ohio State University (B.Sc. and M.Sc.) and received his Ph.D. in Immunology from the John Curtin School of Medical Research, the Australian National University (Canberra, Australia). He completed four years of post-doctoral training at Cornell University and the Uniformed Services University of Health Sciences under contract with the National Cancer Institute, National Institutes of Health. He also served four years as a full-time member of the Louisiana State University faculty at the School of Veterinary Medicine prior to joining the biotechnology industry in 1989.
Samir Desai 卡迪拉医疗保健有限公司（Zydus Cadila）
President & Head of BU Biologics 卡迪拉医疗保健有限公司（Zydus Cadila）印度 Industry experience of close to 3 decades having handled sales, training, brand management, marketing and commercial operations. Current role includes commercial operations for vaccines & biologics and small molecules across specialties & geographies, Business Development, In & Out licensing, portfolio planning. Extensively worked in the area of maternal health related public policy advocacy, improving access to HCV medicines etc. Handled vaccines since 2 decades.
Randall Hyer Moderna
MD, PhD, MPH, Senior Vice President, Global Medical Affairs, Moderna, USA Moderna美国 Dr. Hyer has over three decades of experience in medicine and public health in both the public and private sectors. After graduating with distinction from the US Naval Academy, he studied at Duke Medical School and then earned a Ph.D. in molecular biology from Oxford University. He then spent 13 months on the “ice” in Antarctica as the Station Physician for the winter. Dr. Hyer then shifted to public health and vaccines, serving four years at the World Health Organization as a medical officer responding to outbreaks and emergencies including anthrax, Ebola, SARS, avian influenza, as well as tsunamis and earthquakes. In response to the need for effective communication, Randy co-authored a popular WHO handbook on risk and crisis communication during public health emergencies. In industry, Randy’s experience covers vaccines, biologics, biosimilars, and small molecule development. He was pivotal to the 2017 approval of a two-dose adult hepatitis B vaccine (HEPLISAV-B), the first FDA-approved vaccine with a truly novel adjuvant. Beyond development, his responsibilities have included directing vaccine and pharmaceutical safety programs, overseeing vaccine clinical operations and biometrics functions, engaging medical scientists and policy-makers, and managing crises. Randy’s perspectives and contributions span his residing in eight and traveling to 100 plus countries in diverse roles across the public and private sectors.
Joseph Payne Arcturus Therapeutics
总裁兼首席执行官Arcturus Therapeutics美国Joseph E. Payne, is the President and Chief Executive Officer of Arcturus Therapeutics. He serves on Arcturus’s Board since March 2013. He brings with him an exceptional track record of ushering novel therapeutics to the clinic including targeted RNA medicines utilizing lipid-mediated delivery technologies. Joseph’s background includes over 20 years of successful drug discovery experience at Merck Research Labs, DuPont Pharmaceuticals, Bristol-Myers Squibb, Kalypsys, and Nitto as evidenced by over 40 publications and patents, and several investigational new drug (IND) clinical candidates. His academic training includes a Bachelor's Degree in Chemistry, magna cum laude from Brigham Young University, a Master of Science in Synthetic Organic Chemistry from the University of Calgary and Executive Training Certification from MIT Sloan School of Management.
Alexandre, Le Vert Osivax
首席执行官Osivax法国Alexandre has broad experience in healthcare ranging from research and development to commercialization of vaccines and therapeutics. He is an experienced entrepreneur in biotech and innovation. Alexandre is a Board Member of several biotech companies in France and in the US.
Ingrid Kromann 消费物价指数
Head of CMC消费物价指数英国 Ingrid Kromann started 01 March 2020 as Head of CMC, CEPI, UK. The CEPI CMC team is facilitating the vaccine developers in process development and scale-up activities.
Ingrid has a background as a chemical engineer. She has more than 25 years experience of working with vaccines through her employment at Statens Serum Institut, Denmark.
For the last 16 years, Ingrid led the Vaccine development department at Statens Serum Institut and has developed more than 10 different vaccines from research to clinical trials, mostly within Tuberculosis, Polio, and Chlamydia.
Rong Xu Clover Biopharmaceuticals
Senior Vice President, re-Clinical R&D (Vaccine)Clover Biopharmaceuticals中国
Kevin Wang, Ph.D CC-Pharming Ltd.
Chairman/CSOCC-Pharming Ltd.中国
Kiat Ruxrungtham, MD Department of Medicine Chulalongkorn University; and Scientific Chair of the Chula Vaccine Research Center (ChulaVRC)
Professor of MedicineDepartment of Medicine Chulalongkorn University; and Scientific Chair of the Chula Vaccine Research Center (ChulaVRC) Kiat Ruxrungtham, M.D, Scientific Mentor & Founder, Chula VRC & As Scientific Mentor & Founder of Chula VRC, Kiat Ruxrungtham conducts vaccine research work and gathering professors and researchers interested in the research and development of vaccines into Center of Excellence in Vaccine Research and Development. He spent more than 30 years exploring HIV treatment strategies, HIV T cell immunology, vaccine development (including dengue, HIV, and house dust mite (HDM) vaccine); and strategies to improve DNA vaccine immunogenicity. He has supervised and lead Chula VRC’s effect to rapidly advance the promising HDM vaccine candidates from the lab bench to clinical trial.
Ruxrungtham holds a Professor of Medicine from the Department of Medicine, Chulalongkorn University. He is providing teaching and patient care at the King Chulalongkorn Memorial Hospital and is mentoring junior researchers on the vaccine, immunology research, and also on clinical trials. He currently is a vice president for research and innovation, Chulalongkorn University.
He has published more than 230 peer review papers on HIV, immunology, and allergy. He is a faculty member of the faculty 1000 of Medicine, a chief editor of Asia Pacific J of Allergy, and an editorial board member of Immunology, ImmunoTargets and Therapy, Asian Biomedicine, and the Scientific Report. He is also a reviewer for > 9 journals.
拉金德·库马尔·苏里 DCVMN
首席执行官DCVMNRajinder Kumar Suri于2021年1月15日加入DCVMN（发展中国家疫苗制造商网络），担任首席执行官。在此之前，他戴上了Panacea Biotec Ltd.首席执行长兼生物执行官一职。Rajinder在制药和生物领域拥有40多年的丰富经验。产品在印度和国际市场上拥有超过24年的最高管理经验，其中包括在赛诺菲巴斯德印度子公司董事会任职的四年时间。剩下的19年在Pharma工作，其中16年在Lupin工作。 Suri先生拥有超过3年的咨询经验，担任Arete商业顾问公司的首席执行官兼高级顾问。拉金德（Rajinder）从2013年10月至2017年6月一直担任DCAVIN的咨询委员会成员，政策与计划委员会（PPC）的成员，同时还是供应与采购策略GAVI指导委员会的成员。他在与卫生部，印度政府，联合国机构以及世界卫生组织，联合国儿童基金会，比尔和梅琳达·盖茨基金会，克林顿医疗准入倡议等其他全球组织的谈判和互动中发挥了领导作用。 Rajinder还是DCVMN的前成员执行委员会兼副主席，从2014年10月至2016年为期两年。
Vasan K Sambandamurthy 印度联盟
首席执行官印度联盟印度 Vasan Sambandamurthy joined the DBT/Wellcome Trust India Alliance in October 2020 with over 20 years of professional experience in vaccine discovery and drug development. He has previously worked for major global corporations like Novartis, AstraZeneca, and Biocon. At these organizations, Vasan has held senior leadership positions, provided strategic directions, and orchestrated major business operations to develop affordable medicines across multiple therapeutic areas including oncology, diabetes, infectious diseases (specifically in tuberculosis and malaria), and inflammation.
Vasan completed his post-doctoral training as a Howard Hughes Medical Institute (HHMI) fellow at the Albert Einstein College of Medicine in New York. He gained his Ph.D. from the Tuberculosis Research Centre (Indian Council of Medical Research) in Chennai and completed his post-graduate degree in Medical Microbiology from the Christian Medical College and Hospital in Vellore. He went on to leverage his academic training and real-world experience in managing large Research & Development portfolios, interdisciplinary and cross-functional global teams, regulatory submissions, and global alliances to advance diverse classes of molecules into clinical development.
In his spare time, Vasan is a prolific long-distance runner, avid trekker, and classical music enthusiast.
Farshad Guirakhoo博士 COVAXX和VAXXINITY
首席科学官COVAXX和VAXXINITY美国
Elena Smith 赛诺菲巴斯德
Deputy Director, Analytical Expert - Quality (Protein Sciences Site)赛诺菲巴斯德美国
埃特尔瓦·卡迪利（Etleva Kadilli） 联合国儿童基金会
供应部总监联合国儿童基金会丹麦哥本哈根Etleva（Eva）Kadilli是位于丹麦哥本哈根的联合国儿童基金会供应司司长，负责联合国儿童基金会的全球供应链职能，每年的支出超过38亿美元。她以这种身份，领导儿童基金会的直接方案，并与各国政府和合作伙伴合作，为儿童提供有效，高效和合乎道德的基本和紧急物资。 Kadilli女士负责管理联合国儿童基金会对人道主义危机的供应响应，目前领导该组织对COVID-19大流行的战略采购和后勤应急响应。她以这种身份代表联合国儿童基金会在联合国COVID供应链工作队中担任代表，并在许多其他全球论坛中代表该组织，包括联合国采购改革的机构间参与，以及疫苗联盟Gavi董事会的候补成员。 Kadilli女士还是Gavi的审计和财务委员会以及市场敏感决策委员会的成员。 Kadilli女士是联合国儿童基金会的近25年工作人员，在总部和总部外以及发展和紧急情况下，包括阿尔巴尼亚，刚果民主共和国（DRC），冈比亚和索马里均担任过多个职务。 。 Kadilli女士自2011年以来一直在联合国儿童基金会的供应部门工作，此前她曾在该部门担任供应链副总监，负责监督负责合同政策和程序，质量保证，全球物流运营和应急响应的团队。她的其他职责还包括合同负责人，负责采购监督和合规工作。卫生技术供应的合同经理和医疗部门团队负责人，以支持MNCH和HIV / AIDS计划，包括在2014-2016年埃博拉疫情期间。
陈玉娇 北京CC-Pharming
联合创始人兼执行副总裁北京CC-Pharming中国
Dr. Gaurab Sircar Visva Bharati University, Santiniketan,
教授Visva Bharati University, Santiniketan,印度Currently working as a DBT/Wellcome Trust India Alliance Early Career Fellow at Visva-Bharati, Santiniketan. I obtained my MSc in Botany from Calcutta University followed by Ph.D. from Bose Institute, Kolkata. Following 3 years of postdoctoral training from Bose Institute and then from Harvard Medical School, Boston, MA, USA, I joined Visva-Bharati as an ECF. For the last 10 years, I have been pursuing research in the field of ‘Molecular Allergology and Clinical Immunology’ with an aim to develop molecular diagnostics and immunotherapeutics for allergic diseases. I am currently working on designing recombinant vaccines for patient-tailored immunotherapy to treat allergic asthma triggered by Aspergillus fumigatus, a ubiquitously present pathogenic mold.
Sanjeev Kumar, Ph.D International Centre for Genetic Engineering and Biotechnology (ICGEB),
DBT/Wellcome Trust India Alliance Early Career Fellow, ICGEB-Emory Vaccine ProgramInternational Centre for Genetic Engineering and Biotechnology (ICGEB), 印度He is presently working as a DBT-Wellcome Trust India Alliance Early Career Fellow at ICGEB-Emory Vaccine Program, ICGEB, Delhi, India. His present work involves studying the humoral antibody response against DENV and SARS-CoV-2 infections; isolation and characterization of human monoclonal neutralizing antibodies for viral infections and engineered viral antigen-based vaccine design using Reverse Vaccinology 2.0 approach. In the past as a part of his Ph.D. at AIIMS, New Delhi, India under the supervision of Prof. Kalpana Luthra, he worked on isolation and characterization of human anti-HIV-1 monoclonal antibodies using high-throughput antigen specific single B cell sorting technology. He has designed a protein based HIV-1C immunogen as a part of his EMBO short-term fellowship, Rogier Sanders Lab, AMC, Amsterdam. Further, he gained expertise in 10x genomics for single B cell-based Next-gen sequencing and BCR repertoire RNA-seq and data analysis from Dennis Burton Lab, The Scripps Research Institute, San Diego, CA, USA as a part of HIV Research Trust Scholarship, UK. In his master’s thesis work, he made human cross-neutralizing anti-HIV-1 scFvs against the CD4bs from a phage library constructed from HIV-1 clade-C infected Indian pediatric donors.
Ajoy Chakrabarti 比尔和梅琳达·盖茨基金会
Portfolio And Platform Lead比尔和梅琳达·盖茨基金会美国Dr. Chakrabarti has over 25 years of diverse product development experience in both pharmaceutical and biotechnology companies. He joined the Gates Foundation in 2016, working across multiple polio vaccine programs to provide strategic guidance and product development expertise as part of the global effort to eradicate polio. Prior to joining the Foundation, he spent eight years leading cross-functional development teams working on anthrax therapeutics and vaccines, as well as nerve agent antidotes at Emergent BioSolutions
马修·唐纳姆 消费物价指数
可持续制造主管消费物价指数英国Downham博士在伦敦南岸理工大学（英国）获得了工业生物学理学学士学位（荣誉学位），其中包括在勃林格曼曼海姆（DE）的工作。然后，他完成了博士学位。拥有生物化学工程专业的博士学位（英国伯明翰大学），生物分子科学的博士后研究奖学金（英国的利物浦约翰·摩尔大学）和进修/高等教育学的研究生证书（英国的博尔顿学院）。他于1997年加入生物制药行业，曾在Protherics（英国），Bavarian Nordic＆Morphosys（DE），诺华疫苗与诊断（IT）和AstraZeneca（英国）工作。 Downham博士致力于针对感染，高血压，炎症和肿瘤适应症的疫苗，抗体或酶疗法的临床前和早期临床开发。他是欧洲注册毒物学家（2010-18）；欧洲疫苗欧洲流感工作组主席（2017-20）;国际药品生产商协会联合会流感疫苗供应工作组司库（2017-20）; IFPMA生物多样性公约工作组副主席（2018-20）。 Downham博士还与他人合着了29种出版物/摘要和3项国际专利，并于2021年1月加入了流行病防备创新联盟（英国），成为可持续制造牵头人。主要相关信息：荣誉工业生物学理学士学位（英国伦敦南岸理工学院，德国勃林格曼曼海姆），博士学位。生物化学工程（英国伯明翰大学），PGCE（英国博尔顿学院），博士后研究奖学金–生物分子科学（英国利物浦约翰摩尔大学）和欧盟注册毒物学家（英国皇家生物学会，2010-'18） 25年的国际生物制药行业：勃林格曼海姆（DE），Protherics（英国），巴伐利亚北欧和Morphosys（DE），诺华疫苗与诊断（IT），阿斯利康（英国）。
Nguyen Tuyet Nga 路径
Vietnam Country Director, PATH, Vietnam 路径越南 Dr. Nguyen Tuyet Nga is PATH’s country director for Vietnam. She leads a broad portfolio of projects that focus on vaccines and immunization; infectious diseases including HIV, tuberculosis, and malaria; non-communicable diseases including heart disease and diabetes; infection prevention and control and antimicrobial resistance; and health systems strengthening via digital tools, improved data and data use culture, and strengthened primary health care. Nga also leads on regional programs that provide support to health systems and providers in Cambodia, Laos, and other countries in the region.
Nga is a medical doctor with particular experience in epidemiology, infectious disease control, vaccine development, and immunization programs. She has more than 25 years of experience in vaccine development and production (including clinical trials and licensing), immunization programming, infectious disease control including for HIV and tuberculosis, and in leading teams that promote the use of digital solutions and data for more effective, efficient, and resilient health systems.
Nga has been working with PATH since 2009, working as a technical advisor and in program management roles across PATH’s vaccines and immunization, tuberculosis, and digital solutions and data portfolios. Nga became the Vietnam Program Team Leader in 2014, the Deputy Country Director in 2018, and the Vietnam Country Director in 2019.
Before joining PATH, Nga was the head of the Research and Development Department at VABIOTECH, one of the largest vaccine companies in Vietnam, and worked as a researcher in the National Institute of Hygiene and Epidemiology. She holds an MD from Hanoi Medical University, a Ph.D. in Epidemiology from the National Institute of Hygiene and Epidemiology, and completed post-doctoral training in emerging infectious diseases from the United States Center for Disease Control and Prevention in Atlanta.
Frank Malinoski Eveliqure Biotechnologies
首席营销官Eveliqure Biotechnologies奥地利 Dr. Malinouski has extensive, over twenty years of vaccine experience in preclinical, clinical, regulatory, medical affairs (post-licensure), safety, and business development, including board membership. He received a BA degree from Colby College in 1976 and trained in microbiology (Ph.D.; Rutgers University, 1981) and medicine (MD; Albany Medical College, 1985).
Throughout his career, he held numerous executive positions such as Director of Clinical Research at Lederle-Praxis Biologicals, Senior Vice President of Clinical and Medical Affairs at Nabi Biopharmaceuticals, Vice President of Medical Affairs at Wyeth, Chief Medical Officer, and Senior Vice President of Development for Oxxon Therapeutics, Inc, and Vice President and then Senior Vice President of Medical and Scientific Affairs at MedImmune, LLC. He served on the board of LigoCyte Pharmaceuticals, Inc., a biotech vaccine company in Bozeman, MT from March 2008 to March 2009 and is involved with the North Carolina Biotechnology Center in Wilmington, NC. Dr. Malinoski has authored or co-authored multiple scientific and vaccine-related publications and is a member of several editorial boards.
Daniel R. Vlock Alopexx
MD – Founder, CEOAlopexx
Dave E. Anderson VBI Vaccines
首席科学官VBI Vaccines美国A dynamic and well-published immunologist with broad expertise in the areas of vaccine development, autoimmunity and tumor immunology, Dr. Anderson joined VBI full time in 2009 from Harvard Medical School, where he held a position as Assistant Professor. As a co-founder and Chief Scientific Officer of VBI, Dr. Anderson is an inventor of much of the Company’s intellectual property and actively manages its ongoing expansion. Dr. Anderson holds a Ph.D. from Harvard University and a B.S. from the University of California at Davis.
Ada Wong 赛诺菲
Asia Public Affairs Lead赛诺菲新加坡
Per Fischer Minervax
CEO,Minervax丹麦 Dr. Fischer is the CEO of MinervaX. has 25 years of experience in the biotech and pharmaceutical industry within product development and business development. He has founded and run several biotech companies, worked as a biotech consultant, and been an entrepreneur in residence with Novo Holdings. Primary therapeutic areas have been immunology, vaccines, hemostasis, and oncology. He holds a D.Phil. from the University of Oxford.
Kirill Dmitriev Russian Direct Investment Fund
首席执行官Russian Direct Investment Fund俄国 Kirill Dmitriev heads the Russian Direct Investment Fund - one of the world's leading sovereign funds with a reserved capital of $10 billion under management. RDIF was established in 2011 on the initiative of the President and the Chairman of the Government of the Russian Federation. In all transactions, RDIF acts as a co-investor alongside major international investors, playing the role of a catalyst in attracting direct investment into Russia. RDIF has successfully invested with foreign partners in more than 90 projects totaling 2.1 trillion rubles and covering 95% of the regions of the Russian Federation. RDIF has established joint strategic partnerships with leading international co-investors from more than 15 countries totaling more than $40 billion.
Prior to becoming CEO of RDIF in 2011, Kirill Dmitriev headed a number of large private equity funds and completed a series of landmark transactions for Russia, including the sale of Delta Bank to General Electric, Delta Credit Bank to Société Générale, CTC Media to Fidelity Investments, among others. Mr. Dmitriev began his career at Goldman Sachs and McKinsey & Company.
He was appointed by the President of Russia as a member of the BRICS and APEC Business Councils. He serves as a member of the supervisory board of ALROSA, and of the boards of directors of Transneft, Rostelecom, Gazprombank, MDMG, Russian Railways , Rosseti and Skolkovo Foundation. Mr. Dmitriev is also on the boards of trustees of the Mariinsky Theatre, Lomonosov Moscow State University and National History Fund. He is Vice President of the Russian Union of Industrialists and Entrepreneurs.
S S Vasan CSIRO
Team LeaderCSIRO澳大利亚
Luis Rios-Nogales ILiAD Biotechnologies
首席医疗官ILiAD Biotechnologies美国
2021 赞助商与参展商
展示您的解决方案 致亚洲顶级疫苗执行人员
2021年亚洲疫苗世界大会将为您提供机会，向市场宣传您的产品，并与重要的行业人物一起成为自己所在领域的领导者！这是一个难得的机会，可以将您的品牌和业务定位在亚洲顶级疫苗高管之前。确保您可以访问该地区最热门的生命科学子行业。
市场 行业情报
最新！电子书：治疗和预防性疫苗管道（亚洲）
独家！疫苗开发中的挑战-监管角度
简体中文 
English 
日本語 
한국어 
繁體中文